GlassScriptPhysician profile
Tamara Lenis
NPI 1982947842
$11,824.13
in general payments reported to CMS, 2019-2025
16 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $35.96 · 2021: $20.60 · 2022: $6,040 · 2023: $575 · 2024: $3,429 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738 · Travel and Lodging: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.66 |
| Travel and Lodging | $1,912.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $4,313.54 | 2022-2024 | |
| Genentech USA, INC. | $3,870.81 | 2022-2024 | Vabysmo, Lucentis |
| Alcon Vision LLC | $1,236.31 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $725.75 | 2022-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $458.29 | 2023-2025 | |
| Alimera Sciences, INC. | $209.16 | 2022-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $197.47 | 2023-2025 | Vyzulta, Xipere, Visudyne |
| Astellas Pharma US INC | $167.43 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $134.66 | 2021-2025 | Syfovre |
| Ocular Therapeutix, INC. | $123.60 | 2024 | Dextenza |
| Regeneron Pharmaceuticals, INC. | $103.92 | 2022 | |
| Genentech, INC. | $101.28 | 2022 | |
| Ani Pharmaceuticals, INC. | $74.18 | 2025 | Iluvien, Yutiq |
| Neurotech Pharmaceuticals, INC. | $36.50 | 2025 | |
| Harrow Eye, LLC | $35.65 | 2025 | Iheezo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $35.58 | 2024 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Lenis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.